Kura Oncology, Inc. announced dosing of the first patient with KO-2806, the Company's next-generation farnesyl transferase inhibitor (FTI), in combination with the tyrosine kinase inhibitor (TKI) cabozantinib in the clear cell renal cell carcinoma (ccRCC) cohort of the Phase 1 portion of the FIT-001 trial. Kura Oncology is a next-generation inhibitor of farnesyl transferase inhibitor of farnesyl transferases designed to improve upon the potency, pharmacokinetic and physicochemical properties of earlier FTI drug candidates. At the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Kura presented promising preclinical data supporting the rationale for combining KO-2806 with distinct classes of targeted therapies, including tyrosine kinase inhibitors, KRASG12C inhibitors and KRASG12D inhibitors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.65 USD | +3.42% | +12.09% | +36.65% |
Apr. 22 | Sector Update: Health Care Stocks Advance Premarket Monday | MT |
Apr. 22 | Kura Oncology Gets Breakthrough Designation For Leukemia Therapy | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.65% | 1.5B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- KURA Stock
- News Kura Oncology, Inc.
- Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma